GENF — Genflow Biosciences Income Statement
0.000.00%
Last trade - 00:00- £3.52m
- £3.24m
Annual income statement for Genflow Biosciences, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 0.142 | 0.988 | 1.33 | 1.63 | 1.59 |
| Operating Profit | -0.142 | -0.988 | -1.33 | -1.63 | -1.59 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.142 | -0.988 | -1.34 | -1.63 | -1.59 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.142 | -0.988 | -1.34 | -1.63 | -1.59 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.142 | -0.988 | -1.34 | -1.63 | -1.59 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.142 | -0.988 | -1.34 | -1.63 | -1.59 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0 | -0.006 | -0.005 | -0.006 | -0.005 |